摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2-羧基噻吩-3-基)乙酸酐 | 104292-92-4

中文名称
(2-羧基噻吩-3-基)乙酸酐
中文别名
——
英文名称
(2-carboxythiophene-3-yl)acetic acid anhydride
英文别名
2-carboxythiophene-3-acetic anhydride;4H-thieno[2,3-c]pyran-5,7-dione
(2-羧基噻吩-3-基)乙酸酐化学式
CAS
104292-92-4
化学式
C7H4O3S
mdl
——
分子量
168.173
InChiKey
XCJXKLAHBPQLRB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    138-140 °C(Solv: benzene (71-43-2))
  • 沸点:
    346.3±42.0 °C(Predicted)
  • 密度:
    1.531±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    71.6
  • 氢给体数:
    0
  • 氢受体数:
    4

SDS

SDS:7c7f87de4c1fd7993c491d5c6061c59b
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2-羧基噻吩-3-基)乙酸酐 生成 4-acetoxy-7,7-ethylenedioxy-11-hydroxy-6,7,8,9-tetrahydroanthra<2,3-b>thiophene-5,10-dione
    参考文献:
    名称:
    异蒽环霉素的新合成策略:道柔霉素D环噻吩类似物的全合成
    摘要:
    适当的官能化的邻苯二甲酸酐的噻吩类似物的强碱诱导的环加成反应构成了对道诺霉素D环噻吩类似物(和)的高度区域专一性和便捷的途径。
    DOI:
    10.1016/s0040-4039(00)96434-7
  • 作为产物:
    描述:
    2-(carboxymethyl)thiophene-3-carboxylic acid(乙氧基乙炔基)(三甲基)硅烷 作用下, 以 1,2-二氯乙烷 为溶剂, 反应 24.0h, 以100%的产率得到(2-羧基噻吩-3-基)乙酸酐
    参考文献:
    名称:
    Facile and efficient syntheses of carboxylic anhydrides and amides using (trimethylsilyl)ethoxyacetylene
    摘要:
    DOI:
    10.1021/jo00372a010
点击查看最新优质反应信息

文献信息

  • Reaction of heteroaromatic analogs of homophthalic anhydride: Synthesis of hetero analogs of peri-hydroxy polycyclic aromatic compounds, isocoumarins, isoquinolinones, and related compounds.
    作者:YASUYUKI KITA、SHINICHIRO MOHRI、TERUHISA TSUGOSHI、HATSUO MAEDA、YASUMITSU TAMURA
    DOI:10.1248/cpb.33.4723
    日期:——
    The reactions of heterohomophthalic anhydrides, 3-carboxy-1-methylindole-2-acetic anhydride (4), 2-carboxybenzo [b] furan-3-acetic anhydride (5), 2-carboxythiophene-3-acetic anhydride (6), and 3-carboxy-1, 4-dimethylpyrrole-2-acetic anhydride (23) with carbon-carbon multiple bonds (C=C and C≡C), acylating agents, and cyclic imines are described. Treatment of the anhydrides (4-6) with various compounds containing carbon-carbon multiple bonds (7-10) in the presence of a strong base caused cycloaddition with spontaneous extrusion of carbon dioxide to give the corresponding linearly condensed peri-hydroxy heteroaromatic compounds (11-19), regioselectively. Base-catalyzed acylation of 4 with acetic anhydride and β, β-dimethylacryloyl chloride gave 3, 5-dimethylpyrano [4, 3-b] indol-1 (5H)-one (21) and 3, 3, 11-trimethyl-3, 4-dihydropyrano [4', 3' : 2, 3]-pyrano [4, 5-b] indole-1, 6 (11H)-dione (22), respectively. Reaction of the anhydrides (4, 6, and 23) with 3, 4-dihydroisoquinoline (24) gave the corresponding condensation products, 14-carboxy-13-methyl-5, 6, 14, 14a-tetrahydrobenz [a] indolo [3, 2-g] quinolizin-8 (13H)-one (25), 12-carboxy-5, 6, 12, -12a-tetrahydrobenzo [a] thieno [2, 3-g] quinolizin-8-one (26) and 12-carboxy-11-methyl-5, 6, 12, 12a-tetrahydrobenzo [a] pyrrolo [3, 2-g] quinolizin-8 (11H)-one (27), in high yields.
    杂环邻苯二甲酸酐、3-羧基-1-甲基吲哚-2-乙酸酐 (4)、2-羧基苯并[b]呋喃-3-乙酸酐 (5)、2-羧基噻吩-3-乙酸酐 (6)、3-羧基-1, 4-二甲基吡咯-2-乙酸酐 (23) 与碳-碳多键(C=C 和 C≡C)、酰化剂和环状亚胺的反应、和 3-羧基-1,4-二甲基吡咯-2-乙酸酐(23)的碳-碳多键(C=C 和 C≡C)、酰化剂和环状亚胺。在强碱存在下,将酸酐(4-6)与各种含有碳碳多键的化合物(7-10)进行处理,可引起环化反应,并自发挤出二氧化碳,从而得到相应的线性缩合过羟基杂芳香族化合物(11-19),且具有区域选择性。在碱催化下,4 与乙酸酐和 β,β-二甲基丙烯酰氯发生酰化反应,分别得到 3,5-二甲基吡喃并[4,3-b]吲哚-1 (5H)-酮(21)和 3,3,11-三甲基-3,4-二氢吡喃并[4',3' : 2,3]吡喃并[4,5-b]吲哚-1,6 (11H)-二酮(22)。酸酐(4、6 和 23)与 3,4-二氢异喹啉(24)反应得到相应的缩合产物,即 14-羧基-13-甲基-5,6,14,14a-四氢苯并[a]吲哚并[3,2-g]喹嗪-8 (13H)-酮(25)、高产率的 12-羧基-5,6,12,-12a-四氢苯并[a]噻吩并[2,3-g]喹嗪-8-酮 (26) 和 12-羧基-11-甲基-5,6,12,12a-四氢苯并[a]吡咯并[3,2-g]喹嗪-8 (11H)-one (27)。
  • SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF
    申请人:JAGTAP Prakash
    公开号:US20100261706A1
    公开(公告)日:2010-10-14
    Provided herein are tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analogs and derivatives, compositions comprising an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog and/or derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, a reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, an ocular or opthalmologic disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, contrast induced nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog or derivative.
    本文提供四环1H-吲哚[1,2-b]吡啶-2(5H)-酮类似物和衍生物,包括含有效量四环1H-吲哚[1,2-b]吡啶-2(5H)-酮类似物和/或衍生物的组合物以及治疗或预防炎症性疾病、再灌注损伤、糖尿病、糖尿病并发症、器官移植引起的再氧化损伤、缺血症、神经退行性疾病、肾功能衰竭、血管疾病、心血管疾病、眼部或眼科疾病、癌症、早产并发症、心肌病、视网膜病、肾病、造影剂诱导性肾病、神经病和勃起功能障碍或尿失禁的方法,包括向需要的受体施用有效量的四环1H-吲哚[1,2-b]吡啶-2(5H)-酮类似物或衍生物。
  • [EN] SUBSTITUTED TETRACYCLIC 1H-INDENO (1,2-B) PYRIDINE-2 (5H)-ONE ANALOGS THEREOF AND USES THEREOF<br/>[FR] ANALOGUES TÉTRACYCLIQUES SUBSTITUÉS DE 1H-INDÉNO(1,2-B)PYRIDINE-2(5H)-ONE ET LEURS UTILISATIONS
    申请人:INOTEK PHARMACEUTICALS CORP
    公开号:WO2010077663A3
    公开(公告)日:2011-02-24
  • KITA, YASUYUKI;MOHRI, SHIN-ICHIRO;TSUGOSHI, TERUHISA;MAEDA, HATSUO;TAMURA+, CHEM. AND PHARM. BULL., 1985, 33, N 11, 4723-4731
    作者:KITA, YASUYUKI、MOHRI, SHIN-ICHIRO、TSUGOSHI, TERUHISA、MAEDA, HATSUO、TAMURA+
    DOI:——
    日期:——
  • KITA YASUYUKI; AKAI SHUJI; AJIMURA NAOMI; YOSHIGI MAYUMI; TSUGOSHI TERUHI+, J. ORG. CHEM., 51,(1986) N 22, 4150-4158
    作者:KITA YASUYUKI、 AKAI SHUJI、 AJIMURA NAOMI、 YOSHIGI MAYUMI、 TSUGOSHI TERUHI+
    DOI:——
    日期:——
查看更多

同类化合物

化合物SEP-363856HYDROCHLORIDE 6,7-二氢-4H-噻吩并[3,2-c]吡喃-4-甲胺 6,7-二氢-4H-噻吩并[3,2-c]吡喃-2-羧酸乙酯 6,7-二氢-4H-噻吩并[3,2-c]吡喃-2-羧酸 5,7-二氢-4H-噻吩并[2,3-c]吡喃-3-羧酸 5,7-二氢-4H-噻吩并[2,3-C]吡喃-3-羧酸乙酯 4-(2-羟基乙基)-4-甲基-6,7-二氢-4h-噻吩并[3,2-c]吡喃 4,5-二氢螺[哌啶-4,7-噻吩并[2,3-c]吡喃] 4',5'-二氢-螺[哌啶-4,7'-[7H]噻吩并[2,3-c]吡喃]-1-羧酸叔丁酯 2-氯-4,5-二氢螺[哌啶-4,7-噻吩并[2,3-c]吡喃] 2-氨基-5,5-二甲基-4,7-二氢-5H-噻吩并[2,3-C]吡喃-3-羧酸叔丁酯 2-氨基-4,7-二氢-5H-噻吩并[2,3-c]吡喃-3-羧酸乙酯 2-氨基-4,7-二氢-5H-噻吩并[2,3-c]吡喃-3-甲腈 2-[[(苯甲酰基氨基)硫代甲酰]氨基]-4,7-二氢-5,5-二甲基-5H-噻吩并[2,3-C]吡喃-3-羧酸 (4-甲基-6,7-二氢-4H-噻吩并[3,2-c]吡喃-4-基)乙酸 (2-羧基噻吩-3-基)乙酸酐 2-(3-hydroxy-2,2-dimethylpropanamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide 2-[[(2S)-2-hydroxy-3,3-dimethylbutanoyl]amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-4-chloro-5-methyl-1H-pyrazole-3-carboxamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-2-fluoronicotinamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-2-oxopyrrolidine-3-carboxamide 2-(1-(hydroxymethyl)cyclopropanecarboxamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide tert-butyl 2-(3-(3,4-dimethoxyphenyl)thioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate trans-6-(benzyloxy)-2-carbamoyl-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-6-(benzyloxy)-2-carbomethoxy-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-6-(benzyloxy)-2-cyano-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-6-(benzyloxy)-2-bromo-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-2-bromo-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran (-)-trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran 5,5-dimethyl-2-nitro-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-2-cyano-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran (-)-trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran cis-7-amino-5,6-dihydro-6-hydroxy-5,5-dimethyl-5H-thieno<3,2-b>pyran 2-[3-(3-trifluoromethyl[1,2,4]oxadiazol-5-yl)-4,7-dihydro-5H-thieno[2,3-c]pyran-2-ylcarbamoyl]cyclopent-1-enecarboxylic acid 2-[3-(4-trifluoromethylthiazol-2-yl)-4,7-dihydro-5H-thieno[2,3-c]pyran-2-ylcarbamoyl]cyclopent-1-enecarboxylic acid 2-[3-(4,5-dimethyloxazol-2-yl)-4,7-dihydro-5H-thieno[2,3-c]pyran-2-ylcarbamoyl]cyclopent-1-enecarboxylic acid 4,4-dimethyl-6,7-dihydro-4H-thieno[3,2-c]pyran 1,1-(3-dimethylamino-3-phenyl-methylene)-3,4-dihydro-1H-2-oxa-9-thia-fluoren N,N-dimethyl-N-{4-phenyl-spiro[cyclohexane-1,4'-1,4'-dihydro-2'H-3'-oxa-9'-thiafluoren]-4-yl}amine triflate N,N-dimethyl-N-{4-phenyl-spiro[cyclohexane-1,4'-1,4'-dihydro-2'H-3'-oxa-9'-thiafluoren]-4-yl}amine trans-5,6-dihydro-6-hydroxy-2,5,5-trimethyl-7-(2-oxopyrrolidin-1-yl)-5H-thieno<3,2-b>pyran trans-2-bromo-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopyrrolidin-1-yl)-5H-thieno<3,2-b>pyran 5-Cyclohexyl-7-oxo-5-phenyl-7H-thieno[3,2-b]pyran-3-carboxylic acid tert-butyl 2-amino-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-methyl-1H-pyrazole-3-carboxamide 5,5-Dimethyl-7-(2-oxo-1-pyrrolidinyl)-5H-thieno[3,2-b]pyran-2-carbonitrile 5,5-Dimethyl-7-(2-oxo-1-pyrrolidinyl)-2-(thiazolin-2-yl)-5-thieno[3,2-b]pyran